State budget 61,3 million to personalized medicine
Funds for personalized medicine, clinical trials, mature clusters, and digitalisation – these are some of the main points for cancer innovation in the newly released state budget.
Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
The workshop in Time Resolved Structural Biology organized by LINXS will be held as an online workshop November 23-25, 2020, each day there will be a session between 13h and 18h (CET; Central European Time). We have opened up the workshop for a larger number of participants so we welcome new registrations!
IMPRESS Norway is a national clinical study starting in 2021 working towards implementing cancer precision medicine in Norway.
Our member Vaccibody signs multi-million-dollar agreement one week before the company is expected on the stock exchange.
InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology.
In this whitepaper, Helen provides tips and good practices for remote audits as an alternative method to conducting traditional on-site audit.
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years. The goal is to create an international innovation hub in cancer. Why? Because personalized medicine is changing cancer innovation.
The start-ups and research projects work within the three life science industries: therapeutics, health tech and bioindustrials.
Together with our member Inven2, we wish to highlight the importance of facilitating clinical studies in Norway – in order to build a strong health industry and provide cancer patients with access to new, innovative treatments.
A new Norwegian technology enables cancer researchers to share data across research groups, institutions and country borders in order to faster reach new discoveries.